Diffusion plays an important role in controlled release drug delivery system. Salbutamol sulphate, which is a bronchodilatory drug for asthma, was microencapsulated with a polyacrylic resin: Eudragit RS 100. Drug release data have been analyzed according to various release kinetics like Zero order, First order and Higuchi kinetics. Suice Higuchi mechanism seemed to predominate, the diffusivity rate constant (KBL) and the diffusion coefficient (Da) were estimated according to Baker-Lonsdale method at pH 1.2.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Breathing Easy in Maricopa County, Arizona: Empowering K-12 Schools With a Novel Nurse Coaching Model to Facilitate Implementation of a County-Wide School-Based Stock Albuterol Inhaler Program.
J Sch Nurs
January 2025
Office of Population Health Sciences, University of Illinois Chicago, Chicago, IL, USA.
To reduce chronic school absenteeism and morbidity and mortality among school-aged children, the prompt administration of albuterol sulfate in schools remains vital. School-based stock inhaler programs are a practical approach to ensure equitable access to life-saving rescue medication for students. School and community partnerships can potentially strengthen program implementation and fidelity by integrating evidence-based practices into routine care.
View Article and Find Full Text PDFBreathing Easy: A Qualitative Analysis of School Nurse and Administrator Perspectives on Stock Inhalers and School-Based Asthma Management.
J Sch Nurs
January 2025
Department of Pediatrics, University of Illinois Chicago College of Medicine, Chicago, IL, USA.
Stock inhalers are unassigned rescue inhalers available for students who experience asthma symptoms at school. This study sought to understand school nurse and administrator perspectives on school-based asthma management and stock inhaler policy implementation. Twenty-three semistructured interviews were conducted with professionals from five high asthma burdened counties in varied geographic settings.
View Article and Find Full Text PDFA 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs.
ACS Pharmacol Transl Sci
January 2025
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, United States Food and Drug Administration (FDA), Silver Spring, Maryland 20993, United States.
Current in vitro cell-based methods, relying on single cell types, have structural and functional limitations in determining lung drug permeability, which is a contributing factor affecting both local and systemic drug levels. To address this issue, we investigated a 3D human lung airway model generated using a cell culture insert, wherein primary human lung epithelial and endothelial cells were cocultured at an air-liquid interface (ALI). To ensure that the cell culture mimics the physiological and functional characteristics of airway tissue, the model was characterized by evaluating several parameters such as cellular confluency, ciliation, tight junctions, mucus-layer formation, transepithelial electrical resistance, and barrier function through assaying fluorescein isothiocyanate-dextran permeability.
View Article and Find Full Text PDFA Retrospective Review of Children Admitted With Acute Severe Asthma to the Paediatric Intensive Care Unit, Red Cross War Memorial Children's Hospital Between 2009 and 2019.
J Paediatr Child Health
January 2025
Paediatric Intensive Care Unit, Red Cross War Memorial Children's Hospital, Senior Lecturer, Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa.
Aim: There is limited data on the PICU outcomes of children with acute severe asthma (ASA) in South Africa. This study aims to describe the profiles and treatment of all children admitted to our PICU with ASA.
Methods: A retrospective audit of all children admitted with ASA to the PICU at Red Cross War Memorial Children's Hospital between 01 January 2009 and 31 December 2019.
Combination Inhaled Corticosteroid and Short-acting Beta2 Agonist (ICS-SABA) Use for Older Adults With Asthma.
Sr Care Pharm
January 2025
2 Feik School of Pharmacy, University of the Incarnate Word, San Antonio, Texas.
The first combination inhaled corticosteroid and short-acting beta₂ agonist (ICS-SABA) was approved by the Food and Drug Administration (FDA) in 2023 for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma exacerbations in patients 18 years of age and older. The recently approved product contains an ICS-albuterol combination. The 2024 Global Initiative for Asthma (GINA) guidelines recommend as-needed ICS-formoterol as the preferred asthma reliever therapy; however, a GINA alternative recommendation is the use of ICS whenever an as-needed (SABA) is used.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!